Viking Therapeutics Past Earnings Performance
Past criteria checks 0/6
Viking Therapeutics's earnings have been declining at an average annual rate of -26.8%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-26.8%
Earnings growth rate
-21.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -10.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26
Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09
Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29Revenue & Expenses BreakdownBeta
How Viking Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -94 | 37 | 77 |
| 31 Dec 23 | 0 | -86 | 37 | 64 |
| 30 Sep 23 | 0 | -81 | 32 | 59 |
| 30 Jun 23 | 0 | -74 | 28 | 53 |
| 31 Mar 23 | 0 | -72 | 22 | 53 |
| 31 Dec 22 | 0 | -69 | 16 | 54 |
| 30 Sep 22 | 0 | -62 | 15 | 48 |
| 30 Jun 22 | 0 | -59 | 13 | 47 |
| 31 Mar 22 | 0 | -57 | 12 | 46 |
| 31 Dec 21 | 0 | -55 | 11 | 45 |
| 30 Sep 21 | 0 | -54 | 10 | 44 |
| 30 Jun 21 | 0 | -50 | 10 | 41 |
| 31 Mar 21 | 0 | -44 | 10 | 35 |
| 31 Dec 20 | 0 | -39 | 11 | 32 |
| 30 Sep 20 | 0 | -36 | 11 | 29 |
| 30 Jun 20 | 0 | -32 | 10 | 27 |
| 31 Mar 20 | 0 | -31 | 10 | 27 |
| 31 Dec 19 | 0 | -26 | 9 | 24 |
| 30 Sep 19 | 0 | -24 | 9 | 22 |
| 30 Jun 19 | 0 | -24 | 8 | 23 |
| 31 Mar 19 | 0 | -23 | 8 | 20 |
| 31 Dec 18 | 0 | -22 | 7 | 19 |
| 30 Sep 18 | 0 | -21 | 7 | 17 |
| 30 Jun 18 | 0 | -20 | 6 | 15 |
| 31 Mar 18 | 0 | -19 | 6 | 13 |
| 31 Dec 17 | 0 | -21 | 5 | 14 |
| 30 Sep 17 | 0 | -20 | 5 | 13 |
| 30 Jun 17 | 0 | -18 | 5 | 12 |
| 31 Mar 17 | 0 | -16 | 5 | 11 |
| 31 Dec 16 | 0 | -15 | 5 | 9 |
| 30 Sep 16 | 0 | -16 | 5 | 10 |
| 30 Jun 16 | 0 | -17 | 6 | 10 |
| 31 Mar 16 | 0 | -21 | 6 | 9 |
| 31 Dec 15 | 0 | -23 | 5 | 7 |
| 30 Sep 15 | 0 | -17 | 4 | 4 |
| 30 Jun 15 | 0 | -12 | 2 | 2 |
| 31 Mar 15 | 0 | -27 | 1 | 22 |
| 31 Dec 14 | 0 | -22 | 1 | 22 |
| 30 Sep 14 | 0 | -23 | 1 | 22 |
| 30 Jun 14 | 0 | -23 | 1 | 21 |
| 31 Mar 14 | 0 | 0 | 0 | 0 |
Quality Earnings: VKTX is currently unprofitable.
Growing Profit Margin: VKTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VKTX is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.
Accelerating Growth: Unable to compare VKTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VKTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: VKTX has a negative Return on Equity (-10.04%), as it is currently unprofitable.